|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ansari J, Palmer DH, Rea DW and Hussain
SA: Role of tyrosine kinase inhibitors in lung cancer. Anticancer
Agents Med Chem. 9:569–575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Muhsin M, Graham J and Kirkpatrick P:
Gefitinib. Nat Rev Drug Discov. 2:515–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lo HS and Lo TB: Cten, a COOH-terminal
tensin-like protein with prostate restricted expression, is
down-regulated in prostate cancer. Cancer Res. 62:4217–4221.
2002.PubMed/NCBI
|
|
5
|
Albasri A, Seth R, Jackson D, Benhasouna
A, Crook S, Nateri AS, Chapman R and Ilyas M: C-Terminal
Tensin-like (CTEN) is an oncogene which alters cell motility
possibly through repression of E-cadherin in colorectal cancer. J
Pathol. 218:57–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Albasri A, Aleskandarany M, Benhasouna A,
Powe DG, Ellis IO, Ilyas M and Green AR: CTEN (C-terminal
tensin-like), a novel oncogene overexpressed in invasive breast
carcinoma of poor prognosis. Breast Cancer Res Treat. 126:47–54.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li YQ, Mizokami A, Izumi K, Narimoto K,
Shima T, Zhang J, Dai J, Keller ET and Namiki M: CTEN/tensin 4
expression induces sensitivity to paclitaxel in prostate cancer.
Prostate. 70:48–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Ghamdi S, Cachat J, Albasri A, Ahmed M,
Jackson D, Zaitoun A, Guppy N, Otto WR, Alison MR, Kindle KB and
Ilyas M: C-Terminal tensin-like gene functions as an oncogene and
promotes cell motility in pancreatic cancer. Pancreas. 42:135–140.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sasaki H, Moriyama S, Mizuno K, Yukiue H,
Konishi A, Yano M, Kaji M, Fukai I, Kiriyama M, Yamakawa Y and
Fujii Y: Cten mRNA expression was correlated with tumor progression
in lung cancers. Lung Cancer. 40:151–155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sjoestroem C, Khosravi S, Zhang G,
Martinka M and Li G: C-Terminal tensin-like protein is a novel
prognostic marker for primary melanoma patients. PLoS One.
8:e804922013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lo SH: C-Terminal tensin-like (CTEN): A
promising biomarker and target for cancer. Int J Biochem Cell Biol.
51:150–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thorpe H, Asiri A, Akhlaq M and Ilyas M:
Cten promotes epithelial-mesenchymal transition through
post-transcriptional stabilization of snail. Mol Carcinog.
56:2601–2609. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Asiri A, Toss MS, Raposo TP, Akhlaq M,
Thorpe H, Alfahed A, Asiri A and Ilyas M: Cten promotes
epithelial-mesenchymal transition (EMT) in colorectal cancer
through stabilisation of src. Pathol Int. 69:381–391. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong SY, Shih YP, Lo A and Lo SH:
Identification of subcellular targeting sequences of Cten reveals
its role in cell proliferation. Biochim Biophys Acta Mol Cell Res.
1866:450–458. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu WM and Liao YC: Downregulation of
C-terminal tensin-like protein (CTEN) suppresses prostate cell
proliferation and contributes to acinar morphogenesis. Int J Mol
Sci. 19:31902018. View Article : Google Scholar
|
|
17
|
Lu X, Gao J, Zhang Y, Zhao T, Cai H and
Zhang T: CTEN induces epithelial-mesenchymal transition (EMT) and
metastasis in non small cell lung cancer cells. PLoS One.
13:e01988232018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho JH, You YM, Yeom YI, Lee DC, Kim BK,
Won M, Cho BC, Kang M, Park S, Yang SJ, et al: RNF25 promotes
gefitinib resistance in EGFR-mutant NSCLC cells by inducing
NF-κB-mediated ERK reactivation. Cell Death Dis. 9:5872018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Xin Z, Chunlu Y, Su C, Qiming S and
Shun X: The lncRNA RHPN1-AS1 downregulation promotes gefitinib
resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Cell
Cycle. 17:1772–1783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu Y, Liu YF, Sebastian O and Glazer PM:
Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via
the histone demethylases, LSD1 and PLU-1. Mol Cancer Res.
16:1458–1469. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li K, Mo C, Gong D, Chen Y, Huang Z, Li Y,
Zhang J, Huang L, Li Y, Fuller-Pace FV, et al: DDX17
nucleocytoplasmic shuttling promotes acquired gefitinib resistance
in non-small cell lung cancer cells via activation of β-catenin.
Cancer Lett. 400:194–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duan Q, Pang C, Chang N, Zhang J and Liu
W: Overexpression of PAD4 suppresses drug resistance of NSCLC cell
lines to gefitinib through inhibiting Elk1-mediated
epithelial-mesenchymal transition. Oncol Rep. 36:551–558. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng W, Xie Q, Liu S, Ji Y and Jin L: KLF4
promotes c-met amplification-mediated gefitinib resistance in
NSCLC. Cancer Sci. 109:1775–1786. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiao D, Chen J, Li Y, Tang X, Wang J, Xu
W, Song J, Li Y, Tao H and Chen Q: miR-1-3p and miR-206 sensitizes
HGF-induced gefitinib-resistant human lung cancer cells through
inhibition of c-Met signalling and EMT. J Cell Mol Med.
22:3526–3536. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao X, Lai S, Hu F, Li G, Wang G, Luo X,
Fu X and Hu J: miR-19a contributes to gefitinib resistance and
epithelial mesenchymal transition in non-small cell lung cancer
cells by targeting c-Met. Sci Rep. 7:29392017. View Article : Google Scholar : PubMed/NCBI
|
